imiquimod has been researched along with Angiogenesis, Pathologic in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunner, SM; Ebner, S; Holub, BS; Kofler, B; Koller, A; Lang, R; Reitsamer, HA; Schwarzenbacher, D; Sternberg, F; Stockinger, J; Trost, A; Vidali, S | 1 |
| Gao, Q; Liu, JH; Luo, DQ; Wang, F; Wu, HH; Zhao, YK | 1 |
| Barber, G; Creagh, EM; Kenealy, S; Lavelle, EC; Liddicoat, A; Manils, J; Munoz-Wolf, N; Raverdeau, M | 1 |
| Detmar, M; Huggenberger, R; Kerl, K; Zgraggen, S | 1 |
| Aspord, C; Charles, J; Leccia, MT; Leloup, C; Molens, JP; Plumas, J; Tramcourt, L | 1 |
| Liu, JH; Luo, DQ; Wu, HH; Xie, WL; Zhao, YK | 1 |
| Jia, J; Zhao, YF | 1 |
| Bignon, YJ; Chèvenet, C; Corbin-Duval, A; D'Incan, M; Déchelotte, P; Franck, F; Hesling, C; Madelmont, JC; Mansard, S; Souteyrand, P; Veyre, A | 1 |
| Benninghoff, B; Jablonska, S; Majewski, S; Marczak, M; Mlynarczyk, B | 1 |
| Li, VW; Li, WW | 1 |
2 review(s) available for imiquimod and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Biomarkers: important clues to the pathogenesis of infantile haemangioma and their clinical significance.
Topics: AC133 Antigen; Adjuvants, Immunologic; Aminoquinolines; Antigens, CD; Biomarkers; Calcium-Binding Proteins; DNA-Binding Proteins; Female; Glucose Transporter Type 1; Glycoproteins; Hemangioma, Capillary; Humans; Imiquimod; Infant; Microfilament Proteins; Neoplastic Syndromes, Hereditary; Neovascularization, Pathologic; Peptides; Placenta; Pregnancy; Receptors, Androgen; Skin Neoplasms | 2010 |
Antiangiogenesis in the treatment of skin cancer.
Topics: Adjuvants, Immunologic; Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Agents; Drug Delivery Systems; Humans; Imiquimod; Neovascularization, Pathologic; Signal Transduction; Skin Neoplasms | 2008 |
8 other study(ies) available for imiquimod and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Lack of Galanin Receptor 3 Alleviates Psoriasis by Altering Vascularization, Immune Cell Infiltration, and Cytokine Expression.
Topics: Adult; Animals; Cytokines; Disease Models, Animal; Female; Humans; Imiquimod; Keratinocytes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Neovascularization, Pathologic; Nestin; Neutrophil Infiltration; Neutrophils; Psoriasis; Receptor, Galanin, Type 2; Receptor, Galanin, Type 3; Severity of Illness Index; Skin | 2018 |
Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model.
Topics: Acitretin; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Female; Imiquimod; Mice, Inbred BALB C; Microvessels; Neovascularization, Pathologic; Psoriasis; Signal Transduction; Skin; Thalidomide; Vascular Endothelial Growth Factor A | 2018 |
Caspase-11-Mediated Cell Death Contributes to the Pathogenesis of Imiquimod-Induced Psoriasis.
Topics: Animals; Caspases, Initiator; Cell Death; Cell Proliferation; Disease Models, Animal; Humans; Imiquimod; Inflammation; Interleukin-1beta; Mice; Mice, Knockout; Neovascularization, Pathologic; Psoriasis; Ribonuclease, Pancreatic; Skin | 2019 |
An important role of the SDF-1/CXCR4 axis in chronic skin inflammation.
Topics: Aminoquinolines; Animals; Chemokine CXCL12; Chronic Disease; Dermatitis; Imiquimod; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Receptors, CXCR4; Up-Regulation | 2014 |
Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.
Topics: Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Down-Regulation; Fibroblast Growth Factors; Humans; Imiquimod; Interleukin-8; Melanoma; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Ribonuclease, Pancreatic; Skin Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Imiquimod Increases Cutaneous VEGF Expression in Imiquimod-induced Psoriatic Mouse Model.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Female; Imiquimod; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Psoriasis; Skin; Vascular Endothelial Growth Factor A | 2016 |
In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases.
Topics: Administration, Topical; Aged; Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Gene Expression Regulation; Humans; Imiquimod; Interferon-alpha; Kisspeptins; Matrix Metalloproteinases; Melanoma; Neovascularization, Pathologic; Proteins; Skin Neoplasms; Tissue Inhibitor of Metalloproteinase-1; Tumor Suppressor Proteins; Vascular Endothelial Growth Factors | 2004 |
Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.
Topics: Adjuvants, Immunologic; Aminoquinolines; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bowen's Disease; Cell Line, Tumor; Disease Models, Animal; Humans; Imiquimod; Interferon-alpha; Interleukin-18; Keratinocytes; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; Papillomaviridae; Papillomavirus Infections; Sarcoma; Skin Neoplasms; Tumor Necrosis Factor-alpha | 2005 |